Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

October 4, 2019October 7, 2019

Verzenio-Faslodex Combo Prolongs Survival of Women with Advanced Breast Cancer, Phase 3 Trial Shows

News

Verzenio (abemaciclib) in combination with Faslodex (fulvestrant) prolongs the survival of women with HR-positive, HER2-negative, advanced or metastatic breast cancer who had been treated previously with endocrine therapy, a Phase ... Read more

September 23, 2019

New Herceptin-Perjeta Formulation Shows Promising Safety and Pharmacokinetic Profile, Phase 3 Trial Shows

News

When given together with Herceptin (trastuzumab) at a fixed dose through an under-the-skin (subcutaneous) injection, Perjeta (pertuzumab) reaches levels in the blood in women with HER2-positive breast cancer that is ... Read more

September 4, 2019

FDA Urges Inclusion of Men in Clinical Trials for Breast Cancer Treatment

News

The U.S. Food and Drug Administration (FDA) has drafted a series of recommendations urging the inclusion of men in breast cancer clinical trials, aiming to broaden treatment options for these ... Read more

August 26, 2019September 18, 2019

Grant to Fund CAR T-cell Trial for HER2-Positive BC with Brain Metastases

News

The California Institute for Regenerative Medicine (CIRM) has granted a $9.28 million award to a group of City of Hope researchers carrying out a first-in-human Phase 1 clinical trial testing ... Read more

August 23, 2019August 23, 2019

Oral Paclitaxel Combo Leads to Better Response Rates Than IV Therapy in MBC, Data Shows

News

Treatment with a combination of oral paclitaxel and encequidar led to higher and stronger response rates compared with standard paclitaxel intravenous therapy in women with metastatic breast cancer, topline data from ... Read more

August 7, 2019September 10, 2019

Keytruda Plus Chemo Increases Percentage of TNBC Patients With No Cancer Signs, Interim Analysis Shows

News

Using Keytruda (pembrolizumab) in combination with chemotherapy increased the percentage of patients showing no signs of breast cancer after completing a course of neoadjuvant therapy — treatment to shrink a ... Read more

August 2, 2019

Verzenio-Faslodex Combo Prolongs Survival in Advanced Breast Cancer, Interim Phase 3 Data Show

News

Verzenio (abemaciclib) in combination with Faslodex (fulvestrant) prolongs the survival of women with HR-positive, HER2-negative advanced or metastatic breast cancer who had been previously treated with endocrine therapy, interim analysis ... Read more

July 12, 2019July 12, 2019

Balixafortide-Halaven Combo Seen to Prolong Survival in Advanced Breast Cancer Patients in Phase 1 Trial

News

A combination of Polyphor‘s investigational therapy balixafortide (POL6326) and Eisai‘s Halaven (eribulin) may prolong the survival of women with HER2-negative metastatic breast cancer, a Phase 1 trial shows. The findings were ... Read more

July 10, 2019

Obesity Reprograms Immune Cells in Mammary Tissues to Promote Tumor Development, Study Says

News

Obesity in women with triple-negative breast cancer, the most aggressive kind of breast cancer, reprograms immune cells and creates a chronic inflammatory environment that promotes cancer progression and spread, a ... Read more

June 26, 2019

European Commission Approves Talzenna to Treat Some Breast Cancers

News

The European Commission (EC) has approved Pfizer‘s Talzenna (talazoparib) for the treatment of patients with advanced forms of HER2-negative breast cancer with BRCA mutations who have been treated with chemotherapy ... Read more